Literature DB >> 20975871

Personalized medicine: a personal view.

S A Narod.   

Abstract

Keywords:  Genetics; personalized medicine; preventive medicine

Year:  2010        PMID： 20975871      PMCID： PMC2949368          DOI： 10.3747/co.v17i5.587

Source DB:  PubMed          Journal:  Curr Oncol        ISSN： 1198-0052            Impact factor:   3.677


× No keyword cloud information.
  10 in total

Review 1.  Prevention and management of hereditary breast cancer.

Authors:  Steven A Narod; Kenneth Offit
Journal:  J Clin Oncol       Date:  2005-03-10       Impact factor: 44.544

2.  Direct-to-patient BRCA1 testing: the Twoj Styl experience.

Authors:  Jacek Gronwald; Tomasz Huzarski; Tomasz Byrski; Tadeusz Debniak; Kelly Metcalfe; Steven A Narod; Jan Lubiński
Journal:  Breast Cancer Res Treat       Date:  2006-06-29       Impact factor: 4.872

3.  Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.

Authors:  M C King; S Wieand; K Hale; M Lee; T Walsh; K Owens; J Tait; L Ford; B K Dunn; J Costantino; L Wickerham; N Wolmark; B Fisher
Journal:  JAMA       Date:  2001-11-14       Impact factor: 56.272

4.  Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update.

Authors:  Jacek Gronwald; Nadine Tung; William D Foulkes; Kenneth Offit; Ruth Gershoni; Mary Daly; Charmaine Kim-Sing; Hakan Olsson; Peter Ainsworth; Andrea Eisen; Howard Saal; Eitan Friedman; Olufunmilayo Olopade; Michael Osborne; Jeffrey Weitzel; Henry Lynch; Parviz Ghadirian; Jan Lubinski; Ping Sun; Steven A Narod
Journal:  Int J Cancer       Date:  2006-05-01       Impact factor: 7.396

5.  Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women.

Authors:  Kelly A Metcalfe; Aletta Poll; Robert Royer; Marcia Llacuachaqui; Anna Tulman; Ping Sun; Steven A Narod
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

6.  Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.

Authors:  Tomasz Byrski; Jacek Gronwald; Tomasz Huzarski; Ewa Grzybowska; Magdalena Budryk; Malgorzata Stawicka; Tomasz Mierzwa; Marek Szwiec; Rafal Wisniowski; Monika Siolek; Rebecca Dent; Jan Lubinski; Steven Narod
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

Review 7.  CYP2D6 and tamoxifen: DNA matters in breast cancer.

Authors:  Janelle M Hoskins; Lisa A Carey; Howard L McLeod
Journal:  Nat Rev Cancer       Date:  2009-08       Impact factor: 60.716

8.  The contribution of founder mutations to early-onset breast cancer in French-Canadian women.

Authors:  P Ghadirian; A Robidoux; P Zhang; R Royer; M Akbari; S Zhang; E Fafard; M Costa; G Martin; C Potvin; E Patocskai; N Larouche; R Younan; E Nassif; S Giroux; S A Narod; F Rousseau; W D Foulkes
Journal:  Clin Genet       Date:  2009-11       Impact factor: 4.438

9.  International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.

Authors:  Kelly A Metcalfe; Daphna Birenbaum-Carmeli; Jan Lubinski; Jacek Gronwald; Henry Lynch; Pal Moller; Parviz Ghadirian; William D Foulkes; Jan Klijn; Eitan Friedman; Charmaine Kim-Sing; Peter Ainsworth; Barry Rosen; Susan Domchek; Teresa Wagner; Nadine Tung; Siranoush Manoukian; Fergus Couch; Ping Sun; Steven A Narod
Journal:  Int J Cancer       Date:  2008-05-01       Impact factor: 7.396

10.  Uptake of clinical genetic testing for ovarian cancer in Ontario: a population-based study.

Authors:  Kelly A Metcalfe; Isabel Fan; John McLaughlin; Harvey A Risch; Barry Rosen; Joan Murphy; Linda Bradley; Susan Armel; Ping Sun; Steven A Narod
Journal:  Gynecol Oncol       Date:  2008-11-20       Impact factor: 5.482
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.